Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 413-010-9 | CAS number: 6613-44-1 DMBC
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
PARAMETERS
Physico-chemical Properties:
It has a molecular weight of 168.6 and at room temperature it is a colourless, clear liquid, with a freezing temperature of 4 °C and a boiling temperature of 239 °C. Its relative density is 1.138 at 20 °C and vapour pressure is 5.2 Pa at 25 °C. The surface tension of DMBC is 64.6 mN/m 21 °C. The substance is unstable in water, being immediately hydrolysed to the corresponding acid. The water solubility of the hydrolysis product (dimethylbenzoic acid) was 79 mg/L at 20 °C and the test substance was found to be miscible with fat in all proportions at 37 °C. The calculated partition coefficient was log Pow 2.85 (approximately).
Toxicity
Acute Oral Toxicity:
The LD50 for males was determined to be >5000 mg/kg, and 3162 mg/kg (with 95 % confidence limits of 2000 to 5000 mg/kg bodyweight) for females. The test range was 500, 2000, and 5000 mg/kg bodyweight. There were mortalities at the high dose level (1/6 males and 6/6 females) and clinical signs included passivity, ataxia, tremors, hyperrefiexia, convulsions and twitching of the extremities in the 5000 mg/kg dose level. Other clinical signs in the 2000 and 5000 mg/kg groups included increased salivation, prostration, scant or no faeces, red-stained drop-sheet and red-stained fur surrounding muzzle and/or eyes. The bodyweights for male rats in the 5000 mg/kg group were approximately 30 % less than historical control data. There were no macroscopically visible changes following termination of the surviving test animals. For animals which died during the course of the study, necropsy revealed primarily gastro-intestinal abnormalities such as reddened, black or mucous contents; black material adhered to the mucosa.
Acute Dermal Toxicity:
At a limit dose of 200 mg/kg there were no mortalities. The test substance produced some dermal reactions including erythema and some sores on the perimeter of the application site. All animals were free of systemic toxicity signs. Macroscopic examination of the animals showed no abnormalities.
Skin Irritation:
A single occlusive application of DMBC induced corrosive skin reactions including medium erythema and slight to medium oedema followed by ulcer formation. This ulcerated region gradually changed to scar. These reactions were not fully reversible within 19 days although the skin did show signs of healing.
Eye Irritation:
This test was not conducted on humane grounds. The test substance is expected to be corrosive to the eye.
28 Day Sub-acute Toxicity Study:
Groups of five male and five female rats received 15, 150 or 1000 mg/kg/day in corn oil via oral gavage. There were no mortalities in any group.
In the high dosage group, clinical signs included increased salivation after dosing and red/brown staining of the fur in most rats and red/brown staining of the urogenital region in females. In the 150 mg/kg/day group, increased salivation was also seen in some rats. The alkaline phosphatase (AP) concentration for males and females and the glutamic pyruvate transaminase (GPT) and glutamic oxoacetic transaminase (GOT) concentrations for females were elevated at 1000 mg/kg/day as well as minor changes in cholesterol and glucose levels. For female rats in the other two groups, elevated AP and GPT levels were also evident. Following termination, increased liver and kidney weights were recorded for the 1000 mg/kg/day group. Minimal centilobular hepatocyte enlargement in the liver was evident amongst males treated at 1000 mg/kg/day. Renal changes consisting of dilated cortical tubules with basophilic flattened epithelium, associated with casts in the lumen of the dilated tubules, were seen in both sexes treated at 1000 mg/kg/day. 150 mg/kg/day was determined to be the no observed toxic effect level in the rat.
Mutagenicity: Metabolism
No toxicity or mutagenic activity was seen in the Ames test, either in the absence or presence of S-9 mix. In the in vitro cytogenetics assay, DMBC was not clastogenic in the absence of S-9 mix.
ASSESSMENT
The moderate water solubility and high fat solubility coupled with a reasonably high estimated log Pow value suggest that DMBC is bioavailable and may bioaccumulate. DMBC is not classified on the basis of the acute oral and acute dermal toxicity studies. Animals did not exhibit any signs of systemic toxicity during the acute dermal study which implies that there is minimal to no absorption of the test substance through the skin.
The 28 day sub-acute toxicity study indicates that absorption, distribution, metabolism and excretion of the test substance or its hydrolysis product take place. This is manifested by changes in enzyme levels, elevated liver and kidney weights, changes in liver morphology of male rats and in the kidney morphology of male and female rats. These findings suggest that the liver and/or the kidney are the target organs for toxicity with DMBC.
CONCLUSION
The 28 day oral toxicity study provides evidence that the test substance is absorbed via this route. It also demonstrates that the test material may be distributed systemically and that metabolism occurs in the liver. Various changes in the kidneys suggest that DMBC and/or its metabolites could be excreted renally. There was no evidence of bioaccumulation or dermal absorption found.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.